ReviewFrontiers in immunology2025
Peptide based vesicles for cancer immunotherapy: design, construction and applications.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Machine Learning-Enabled Venom Peptide Platform for Rapid Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2026Article
- β-Hairpin-Based Peptide Hydrogels: The Case of MAX1.Gels (Basel, Switzerland) · 2026Review
- Cancer-Testis Antigens in Immuno Oncology Mechanisms Therapeutic Strategies and Clinical Perspectives.Journal of immunology research · 2026Review
- Therapeutic cancer vaccines in pancreatic cancer.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy has emerged as a powerful strategy for clinical treatment of malignant cancers. Despite the advances, cancer immunotherapy has met several challenges such as the limited efficacy to small subsets of patients, and serious autoimmune side effects. Cancer vaccines that target neoantigens to direct and amplify immune responses against tumors, have shown their efficacy and safety in preclinical and clinical researches. The developed cancer vaccines mainly contained peptide vaccines, mRNA vaccine, cell vaccine and oncolytic virus vaccine. In the last decade, both peptide based vaccines and vesicle based vaccines have attracted enormous attention for personalized vaccine development due to their potent efficacy in different tumor models. Peptide based vesicles are one kind of vesicles that are modified with functional peptides to enhance the efficiency of immune response and anti-cancer effect. In this review, we will introduce the basic characteristics, classification and biological application of vesicles or peptide based cancer vaccines respectively. Then the design and construction of peptide based vesicles will be summarized. Finally, we concluded the biological applications of peptide based vesicles in various cancer types and analyzed the key obstacles to overcome for their clinical applications. We hope this review could provide a better understanding of the construction of peptide based vesicles and their prospects for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.